Neurocrine Biosciences Inc (NBIX)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
NBIX
Neurocrine Biosciences Inc
$163.88
-2.07%
HEALTHCARE · Cap: $16.06B
TAK
Takeda Pharmaceutical Co Ltd ADR
$15.60
+0.97%
HEALTHCARE · Cap: $49.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 145133% more annual revenue ($4.51T vs $3.10B). NBIX leads profitability with a 21.5% profit margin vs 4.3%. TAK appears more attractively valued with a PEG of 0.40. NBIX earns a higher WallStSmart Score of 81/100 (A-).
NBIX
Exceptional Buy81
out of 100
Grade: A-
TAK
Buy57
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Revenue surging 42.2% year-over-year
Earnings expanding 2311.0% YoY
Safe zone — low bankruptcy risk
Keeps 22 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 330.2% YoY
Areas to Watch
Weak financial health signals
3.9% revenue growth
ROE of 2.5% — below average capital efficiency
4.3% margin — thin
Operating margin of 3.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : NBIX
The strongest argument for NBIX centers on PEG Ratio, Revenue Growth, EPS Growth. Profitability is solid with margins at 21.5% and operating margin at 22.8%. Revenue growth of 42.2% demonstrates continued momentum.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.40 suggests the stock is reasonably priced for its growth.
Bear Case : NBIX
The primary concerns for NBIX are Piotroski F-Score.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 42.5x leaves little room for execution misses. Thin 4.3% margins leave little buffer for downturns.
Key Dynamics to Monitor
NBIX profiles as a growth stock while TAK is a value play — different risk/reward profiles.
NBIX carries more volatility with a beta of 0.40 — expect wider price swings.
NBIX is growing revenue faster at 42.2% — sustainability is the question.
NBIX generates stronger free cash flow (137M), providing more financial flexibility.
Bottom Line
NBIX scores higher overall (81/100 vs 57/100), backed by strong 21.5% margins and 42.2% revenue growth. Both earn "Exceptional Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Neurocrine Biosciences Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.
Visit Website →Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?